Cargando…

Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial

BACKGROUND: Trimethylamine N‐oxide (TMAO) may have prothrombotic properties. We examined the association of TMAO quartiles with major adverse cardiovascular events (MACE) and the effect of TMAO on the efficacy of ticagrelor. METHODS AND RESULTS: PEGASUS‐TIMI 54 (Prevention of Cardiovascular Events i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gencer, Baris, Li, Xinmin S., Gurmu, Yared, Bonaca, Marc P., Morrow, David A., Cohen, Marc, Bhatt, Deepak L., Steg, P. Gabriel, Storey, Robert F., Johanson, Per, Wang, Zeneng, Hazen, Stanley L., Sabatine, Marc S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660879/ https://www.ncbi.nlm.nih.gov/pubmed/32366163 http://dx.doi.org/10.1161/JAHA.119.015331

Ejemplares similares

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial
por: Furtado, Remo H. M., et al.
Publicado: (2020)

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019)

Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017)

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50
por: Berg, David D., et al.
Publicado: (2021)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
por: Lee, Kwan Yong, et al.
Publicado: (2022)

Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2022)

Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2023)

Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a “real world” STEMI population: results from the Italian “CARDIO-STEMI SANREMO” registry
por: Sanchez, Federico, et al.
Publicado: (2021)

Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36
por: Zelniker, Thomas A., et al.
Publicado: (2021)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

Despite the Virus, the Special Issue for the 16th Pegasus Student Conference
por: Marcuccio, Salvo, et al.
Publicado: (2020)

Trimethylamine N‐Oxide and Mortality Risk in Patients With Peripheral Artery Disease
por: Senthong, Vichai, et al.
Publicado: (2016)

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
por: Magnani, Giulia, et al.
Publicado: (2021)

Simultaneous Measurement of Urinary Trimethylamine (TMA) and Trimethylamine N-Oxide (TMAO) by Liquid Chromatography–Mass Spectrometry
por: Jia, Xun, et al.
Publicado: (2020)

Effects of Lifestyle Intervention on Plasma Trimethylamine N-Oxide in Obese Adults
por: Erickson, Melissa L., et al.
Publicado: (2019)

Intestinal Microbiota‐Generated Metabolite Trimethylamine‐N‐Oxide and 5‐Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE‐Like Patient Cohort
por: Senthong, Vichai, et al.
Publicado: (2016)

Loop Diuretics Inhibit Renal Excretion of Trimethylamine N-Oxide
por: Li, Daniel Y., et al.
Publicado: (2021)

Commissioning of the UCLA PEGASUS Photoinjector Laboratory
por: Telfer, S, et al.
Publicado: (2001)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
por: Kidd, Stephen K., et al.
Publicado: (2016)

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes
por: Røysland, Ragnhild, et al.
Publicado: (2012)

Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κB
por: Seldin, Marcus M., et al.
Publicado: (2016)

Proposal for a IR Waveguide SASE FEL at the PEGASUS Injector
por: Reiche, S, et al.
Publicado: (2001)

Embedding Algorithms for Quantum Annealers with Chimera and Pegasus Connection Topologies
por: Zbinden, Stefanie, et al.
Publicado: (2020)

The PEGASUS Conferences: A unique avenue to bridge evidence and action
por: Amri, Michelle, et al.
Publicado: (2020)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
por: Amrein, Melissa, et al.
Publicado: (2022)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

PEGASUS: the Design of an Intervention to Facilitate Shared Decision-making in Breast Reconstruction
por: Clarke, A., et al.
Publicado: (2020)

The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial
por: Cohen, Marc, et al.
Publicado: (2014)

Epidemiology and genetics of common mental disorders in the general population: the PEGASUS-Murcia project
por: Navarro-Mateu, Fernando, et al.
Publicado: (2013)

Pegasus, a small extracellular peptide enhancing short-range diffusion of Wingless
por: Magny, Emile G., et al.
Publicado: (2021)

Association of Trimethylamine N-Oxide and Related Metabolites in Plasma and Incident Type 2 Diabetes: The Cardiovascular Health Study
por: Lemaitre, Rozenn N., et al.
Publicado: (2021)

TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI
por: Fuernau, Georg FK, et al.
Publicado: (2009)

Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria
por: Winther, Signe Abitz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jbkpuh0tl330n0eru8antg9rbb